Great Lakes Advisors LLC Buys 893 Shares of Insulet Co. (NASDAQ:PODD)

Great Lakes Advisors LLC grew its stake in Insulet Co. (NASDAQ:PODD) by 34.5% during the 4th quarter, HoldingsChannel reports. The firm owned 3,478 shares of the medical instruments supplier’s stock after acquiring an additional 893 shares during the quarter. Great Lakes Advisors LLC’s holdings in Insulet were worth $908,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of PODD. Mizuho Securities USA LLC grew its position in Insulet by 5,928.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after acquiring an additional 320,416 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Insulet during the 4th quarter worth approximately $69,433,000. Alecta Tjanstepension Omsesidigt bought a new stake in Insulet during the 4th quarter worth approximately $53,184,000. Charles Schwab Investment Management Inc. grew its position in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after acquiring an additional 193,839 shares during the last quarter. Finally, Westfield Capital Management Co. LP grew its position in Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares during the last quarter.

Analysts Set New Price Targets

PODD has been the topic of a number of research analyst reports. Raymond James restated an “outperform” rating and set a $328.00 price target (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Canaccord Genuity Group upped their price objective on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. TD Cowen upped their price objective on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, Citigroup upped their price objective on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Price Performance

PODD opened at $255.44 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company has a fifty day simple moving average of $272.54 and a 200 day simple moving average of $254.96. The stock has a market cap of $17.94 billion, a P/E ratio of 44.12, a P/E/G ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. On average, research analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.47% of the stock is owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.